论文部分内容阅读
目的探讨减半剂量的阿克拉霉素、阿糖胞苷和重组人粒细胞集落刺激因子组成的CAG方案治疗老年人急性髓系白血病(AML)的疗效和安全性。方法 75岁以上老年AML初治28例,采用减半剂量CAG化疗方案诱导及巩固治疗。结果完全缓解17例,部分缓解6例,未缓解5例,完全缓解率60.7%,总有效率82.1%。治疗相关死亡3例。在染色体核型预后良好和预后中等组近期疗效与标准剂量CAG方案相似,且核型预后良好组疗效优于预后中等组。结论减半剂量CAG方案治疗高龄老年AML缓解率高,不良反应轻,患者耐受性好。
Objective To investigate the efficacy and safety of CAG regimen consisting of aclacinomycin, cytarabine and recombinant human granulocyte-colony stimulating factor at half the dose in the treatment of acute myeloid leukemia (AML) in the elderly. Methods AML with initial treatment of AML over 75 years old in 28 cases was treated with CAG chemotherapy at half the dose and consolidation therapy. The results of complete remission in 17 cases, partial remission in 6 cases, 5 cases did not ease, the complete remission rate was 60.7%, the total effective rate was 82.1%. Treatment-related death in 3 cases. The prognosis in the karyotype of good prognosis and prognosis of the middle group with standard dose CAG regimen similar and prognosis of karyotype prognosis better than the prognosis of the moderate group. Conclusions The CAG regimen with half dose reduced the response rate of AML in elderly patients with mild adverse reactions and patients were well tolerated.